SMaRT oncology-2: a two arm parallel group randomised controlled trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder ('Depression Care for People with Cancer') to usual care, compared to usual care alone in cancer patients

Submission date	Recruitment status No longer recruiting	Prospectively registered		
13/05/2008		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
30/05/2008	Completed	[X] Results		
Last Edited 04/04/2022	Condition category Mental and Behavioural Disorders	[] Individual participant data		

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-treating-depression-people-with-cancer-smart-oncology-2

Contact information

Type(s)

Scientific

Contact name

Prof Michael Sharpe

Contact details

School of Molecular and Clinical Medicine
The University of Edinburgh
Kennedy Tower
Royal Edinburgh Hospital
Morningside Park
Edinburgh
United Kingdom

EH10 5HF +44 (0)131 537 6672 michael.sharpe@ed.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers v1.1 12/05/08

Study information

Scientific Title

SMaRT oncology-2: a two arm parallel group randomised controlled trial to determine the effectiveness and cost-effectiveness of adding a complex intervention for major depressive disorder ('Depression Care for People with Cancer') to usual care, compared to usual care alone in cancer patients

Acronym

SMaRT (Symptom Management Research Trials)

Study objectives

- 1. 'Depression Care for People with Cancer' as a supplement to usual care will be more effective than usual care alone in achieving a 50% reduction in baseline 20-item depression score from the Symptoms Checklist (SCL-20D) at 24 weeks
- 2. 'Depression Care for People with Cancer' as a supplement to usual care will cost more than usual care alone but will be more cost effective in achieving improvements in patients depression and quality of life

Ethics approval required

Old ethics approval format

Ethics approval(s)

Scotland A research ethics committee, 31/03/2008, ref: 08/MRE00/23

Study design

Multicentre randomised controlled two-arm parallel-group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Depression in patients with cancer

Interventions

Patients will be randomised to receive:

- 1. Usual care, or
- 2. Usual care plus 'Depression Care for People with Cancer'

Usual care arm:

The usual care of depression from the patient's GP or oncologist (this is routine care and won't be influenced by the researchers)

Usual care plus 'Depression Care for People with Cancer' arm:

In addition to usual care as above a complex intervention for depression delivered by a specially trained cancer nurse under the supervision of a psychiatrist, a maximum of 10 treatment sessions delivered over 16 weeks followed by monthly monitoring of progress until 12 months. The intervention comprises education about depression and its treatments (including antidepressant medication, which would be prescribed by the GP if the patient wishes to take it, and behavioural activation) and problem solving treatment.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Treatment response, measured at 24 week outcome data collection, defined as a reduction of 50% or more in the patients baseline SCL-20D score

Secondary outcome measures

- 1. Remission of major depressive disorder, defined as an SCL-20D score of less than 0.75 at each of 24, 36 and 48 weeks (higher than in primary care trials, to allow for cancer-related somatic symptoms)
- 2. Depression severity, defined for each patient as the average of their SCL-20D score at 24, 36 and 48 weeks

Overall study start date

15/05/2008

Completion date

01/06/2011

Eligibility

Key inclusion criteria

Patients must:

- 1. Have a diagnosis of cancer, with active disease within the last five years
- 2. Be aged 18 or over, either sex
- 3. Be attending a specialist oncology clinic
- 4. Have a predicted survival, estimated by their cancer specialist, of twelve months or more
- 5. Have symptoms that meet Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for major depressive disorder (MDD), with symptoms of the current major depressive episode (MDE) present for four weeks or more using the inclusive approach to diagnosis

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

500

Total final enrolment

500

Kev exclusion criteria

- 1. Patients are unable to provide informed consent to participate
- 2. The episode of depression is chronic (defined as a history of continuous depression for at least two years)
- 3. They are judged to require urgent psychiatric care
- 4. They are receiving active psychiatric or psychological treatment from specialist mental health services
- 5. They have cognitive impairment or communication difficulties (including inability to adequately understand verbal explanations or written information in English) which are incompatible with the intervention
- 6. They have known cerebral metastases
- 7. They are unable to attend regularly for treatment sessions
- 8. The intervention is judged to be inappropriate due to a medical condition which requires alternative treatment
- 9. The intervention is judged to be inappropriate due to a psychiatric condition which requires alternative treatment (psychotic illness, bipolar affective disorder, obsessive compulsive disorder, substance abuse or dependence)
- 10. Their participation in the trial is judged to be inappropriate on other clinical grounds

N.B. Patients receiving active cancer treatments will not be excluded unless they fulfil one or more of the exclusion criteria listed above.

Date of first enrolment

15/05/2008

Date of final enrolment

01/06/2011

Locations

Countries of recruitment

Scotland

United Kingdom

Study participating centre The University of Edinburgh

Edinburgh United Kingdom EH10 5HF

Sponsor information

Organisation

University of Edinburgh

Sponsor details

c/o Marise Bucukoglu
Associate Director (Governance & Sponsorship)
Edinburgh Clinical Trials Unit
Queens Medical Research Institute
47 Little France Crescent
Edinburgh
Scotland
United Kingdom
EH16 4TJ
+44 (0)131 242 9262
marise.bucukoglu@ed.ac.uk

Sponsor type

University/education

Website

http://www.ed.ac.uk/

ROR

https://ror.org/01nrxwf90

Organisation

NHS Lothian - University Hospitals Division (UK)

Sponsor details

Research & Development Office Royal Infirmary of Edinburgh 51 Little France Crescent Edinburgh Scotland United Kingdom EH16 4SA

Sponsor type

Hospital/treatment centre

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK)

Alternative Name(s)

CR UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	30/03/2009		Yes	No
Results article	results	20/09/2014		Yes	No
Results article	results	01/12/2015		Yes	No
Plain English results			04/04/2022	No	Yes